Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

G0776

Sigma-Aldrich

Disialoganglioside-GD2 from bovine brain

~95%, lyophilized powder, semisynthetic

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Numéro CAS:
65988-71-8
Numéro MDL:
MFCD00131133
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Niveau de qualité

200

Pureté

~95%

Forme

lyophilized powder

Température de stockage

−20°C

InChI

1S/C74H134N4O32/c1-4-6-8-10-12-14-16-18-19-21-23-25-27-29-31-33-52(89)78-43(44(84)32-30-28-26-24-22-20-17-15-13-11-9-7-5-2)40-101-69-61(95)60(94)63(50(38-81)104-69)106-70-62(96)67(64(51(39-82)105-70)107-68-55(77-42(3)83)59(93)58(92)49(37-80)103-68)110-74(72(99)100)35-46(86)54(76)66(109-74)57(91)48(88)41-102-73(71(97)98)34-45(85)53(75)65(108-73)56(90)47(87)36-79/h30,32,43-51,53-70,79-82,84-88,90-96H,4-29,31,33-41,75-76H2,1-3H3,(H,77,83)(H,78,89)(H,97,98)(H,99,100)/b32-30+/t43?,44?,45-,46-,47?,48?,49-,50-,51-,53+,54+,55-,56?,57?,58+,59-,60-,61-,62-,63-,64+,65+,66+,67-,68+,69-,70+,73-,74+/m1/s1

Clé InChI

FFILOTSTFMXQJC-QCFYAKGBSA-N

Amino Acid Sequence

Cer-Glc-Gal(NeuAc-NeuAc)-GalNAc

Description générale

Disialoganglioside GD2 is a cell surface-associated glycosphingolipid, which comprises sialic acid moiety and is regarded as a carbohydrate antigen.. It is expressed in the skin melanocytes, central and peripheral nervous system.
Gangliosides are major constituents of neuronal cell membranes and endoplasmic reticulum; contain a sialated polysaccharide chain linked to ceramide through a β-glycosidic linkage; for classification of gangliosides see Svennerholm, L., et al. (eds.), Structure and Function of Gangliosides, New York, Plenum, 1980.

Application

Disialoganglioside-GD2 from bovine brain has been used:
  • in the ganglioside- enzyme-linked immunosorbent assay (ELISA)
  • in capture ELISA with anti-GD2 antibody (ch14.18)
  • as a control to test its effect on reactivating autophagy in primary fibroblasts

Actions biochimiques/physiologiques

Disialoganglioside GD2 is expressed in neuroblastoma, melanoma and small cell lung cancer. It is an immunotherapeutic target and is also regarded as a tumor-associated antigen. GD2 may favor cell migrationin tumors by promoting cell growth, as well as extracellular matrix component attachment.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Anastasia Shibina et al.
Journal of molecular medicine (Berlin, Germany), 91(4), 459-472 (2012-10-12)
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Combining passive immunotherapy with an antibody to the disialoganglioside GD2 (ch14.18/SP2/0) and cytokines with 13-cis-retinoic acid for post-myeloablative maintenance therapy increased survival in high-risk NB, but the overall prognosis
Angelika B Riemer et al.
European journal of immunology, 36(5), 1267-1274 (2006-03-29)
The disialoganglioside GD2, a carbohydrate antigen, is expressed on all tumors of neuroectodermal origin, including melanoma, neuroblastoma, sarcoma and small cell lung cancer. Due to its specific expression on tumor surfaces, GD2 is an attractive target for immunotherapies. The mouse/human
Denis Cochonneau et al.
Cancer letters, 333(2), 194-204 (2013-02-02)
O-Acetyl-GD2 ganglioside is suitable antigen for tumor immunotherapy with specific therapeutic antibody. Here, we investigate the anti-tumor activity of O-acetyl-GD2-specific monoclonal antibody 8B6 on O-acetyl-GD2-positive tumor cells. The results indicated that mAb 8B6 induced growth inhibition of O-acetyl-GD2-expressing tumor cell
Fariba Navid et al.
Current cancer drug targets, 10(2), 200-209 (2010-03-06)
In the development of novel immune therapies for high-risk cancers, one goal is to find tumor targets that are not widely shared by normal cells. One such target is the surface disialoganglioside GD2. This antigen is expressed on the surface
Nidale Tarek et al.
The Journal of clinical investigation, 122(9), 3260-3270 (2012-08-07)
Survival outcomes for patients with high-risk neuroblastoma (NB) have significantly improved with anti-disialoganglioside GD2 mAb therapy, which promotes NK cell activation through antibody-dependent cell-mediated cytotoxicity. NK cell activation requires an interaction between inhibitory killer cell immunoglobulin-like receptors (KIRs) and HLA
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique